• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Type 2 Diabetes Mellitus Treatment Market Trends

    ID: MRFR/Pharma/4214-HCR
    85 Pages
    Rahul Gotadki
    September 2025

    Type 2 Diabetes Mellitus Treatment Market Research Report Information By Treatment (Drug (Insulin, Sensitizers, Sglt-2, Alpha-Glucosidase Inhibitors, Others), Devices (Blood Glucose Monitoring, Insulin Delivery Devices)), By The End User – Forecast Till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Type 2 Diabetes Mellitus Treatment Market Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Market Trends

    Introduction

    In 2024, the world market for the treatment of type 2 diabetes mellitus is experiencing significant changes, a confluence of macroeconomic factors. Technological advances in diabetes management, including the emergence of eHealth and the emergence of continuous blood-glucose monitoring, are reshaping treatment paradigms and increasing patient engagement. Regulation is also stepping up, with health authorities demanding new therapies with improved efficacy and safety profiles. In addition, changing consumer preferences, including a greater preference for a more individualized and more natural approach to health, are influencing treatment choices and market dynamics. These trends are of strategic importance for market players, as they shape not only competitive positioning but also investment strategies and product development in a rapidly evolving landscape.

    Top Trends

    1. Increased Focus on Personalized Medicine
      In recent years, a new trend has been developing in the field of medicine: a tendency towards more individual treatment, with companies such as Eli Lilly and Novo Nordisk investing in the use of genetic material to make treatments more effective. A study has shown that a more individual approach can increase patient adherence by 30 per cent. This development is expected to lead to a reduction in the cost of treatment and increased effectiveness. Other companies are expected to follow suit.
    2. Integration of Digital Health Solutions
      IT solutions, such as mobile health and telemedicine, are increasingly being used in diabetes management. For example, the continuous glucose monitor developed by Abbott Laboratories is connected to a smartphone. The digital tools can lead to a 20 percent improvement in glycemic control, which is why more and more physicians are integrating these tools into their care plans.
    3. Emergence of Novel Therapeutics
      The emergence of new therapeutics, such as GLP-1 agonists and SGLT-2 blockers, has changed the face of the treatment. With the new approvals, the AstraZeneca and Merck companies are at the forefront of the industry. These drugs have been shown in clinical trials to reduce the risk of heart attack by up to 15 percent, which has led to a change in the way of prescribing and a sharp increase in competition.
    4. Government Initiatives for Diabetes Management
      The war against diabetes is being fought by many governments, including the United States, where the National Diabetes Prevention Program is a great success. The aim of these programmes is to reduce the incidence of diabetes by 25% in ten years. Such initiatives are stimulating the pharmaceutical industry to undertake research and development to meet public health needs.
    5. Focus on Preventive Care
      In the past few years, preventive care has been the focus of many organizations, which have advocated early intervention to control risk factors. Data show that lifestyle changes can reduce the risk of type 2 diabetes by 58%. In view of this, the pharmaceutical industry has begun to seek collaboration with the health industry, which can not only broaden its market, but also improve the patient’s outcome.
    6. Advancements in Insulin Delivery Systems
      Insulin injection devices such as smart pens and automatic injection systems are changing diabetes care. Companies like Becton, Dickinson and Company are at the forefront of this change, with devices that improve the accuracy of insulin dosing. These devices can increase patient adherence by up to 40 percent, and studies have shown that this means a more stable market for insulin products.
    7. Increased Collaboration Between Pharma and Tech
      The cooperation between the pharmaceutical and the technical industries is growing rapidly. The goal is to improve the diabetes management solutions. Roche and a number of technology companies, for example, are developing artificial intelligence-based analysis tools for improved patient monitoring. The trend is expected to lead to a better process and patient engagement, which will lead to a change in the competitive environment.
    8. Rising Demand for Biosimilars
      The demand for biosimilars is increasing as health systems look for cost-effective alternatives to expensive biologicals. Biosimilars have been shown to reduce treatment costs by up to 30 per cent. Biosimilars have a role to play in enabling a country’s health care system to be self-reliant and independent. This trend is likely to accelerate the market’s dynamic and encourage more players to enter the biosimilars market.
    9. Emphasis on Patient-Centric Approaches
      The emphases of the future will be patient-centric, focusing on the overall patient experience. Sanofi, for example, is already putting in place a feedback system to adjust its treatments to patients’ needs. Research has shown that a satisfaction level of 92 per cent can lead to a compliance rate of 94 per cent, which has prompted a shift in the way companies design and market their products.
    10. Sustainability in Diabetes Care
      SUITABLE PACKAGING AND PRODUCTION METHODS ARE BEING IMPLEMENTED IN THE WORLD OF DIABETES. For example, Takeda is investing in sustainable practices to reduce its carbon footprint. This trend is likely to influence the buying behaviour of consumers who are concerned about the environment.

    Conclusion: Navigating the Type 2 Diabetes Landscape

    The market for the treatment of type 2 diabetes is characterised by intense competition and considerable fragmentation, with both established and new players competing for market share. In terms of regional trends, a greater focus on individualised treatment is developing, particularly in North America and Europe, where health systems are increasingly introducing new solutions. Strategically, vendors need to take advantage of new technological possibilities such as artificial intelligence for predictive analytics, automation for process efficiency, and sustainability practices to meet evolving consumer expectations. In addition, they must be able to respond to changing market needs quickly. These are the areas in which decision-makers need to concentrate in order to establish themselves as market leaders and to ensure long-term success in this complex market.

    Market Summary

    As per Market Research Future Analysis, the Type 2 Diabetes Mellitus Treatment Market was valued at USD 18.53 Billion in 2023 and is projected to grow to USD 39.18 Billion by 2032, with a CAGR of 9.45% from 2024 to 2032. The market is driven by rising technological advancements, increasing prevalence of diabetes, and growing awareness about the condition. Key players are developing novel drugs and devices, such as Ozempic and Steglatro, to address the unmet medical needs. However, challenges such as high treatment costs and side effects may hinder growth. The Americas dominate the market due to high healthcare expenditure and patient population, while Asia Pacific is the fastest-growing region.

    Key Market Trends & Highlights

    The Type 2 Diabetes Mellitus Treatment Market is witnessing significant growth driven by various factors.

    • Market Size in 2023: USD 18.53 Billion
    • Projected Market Size by 2032: USD 39.18 Billion
    • CAGR from 2024 to 2032: 9.45%
    • 9.4% of the U.S. population had diabetes in 2015, equating to 30.3 million people

    Market Size & Forecast

    2023 Market Size USD 18.53 Billion
    2024 Market Size USD 18.86 Billion
    2032 Market Size USD 39.18 Billion
    CAGR (2024-2032) 9.45%

    Major Players

    Abbott Laboratories, Acon Laboratories, Inc., Adocia, Akros Pharma, Amgen, AstraZeneca, Bayer AG, Becton Dickinson and Company, Biocon, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck, Novartis & Co., Novo Nordisk, Peptron, Pfizer, Roche Diagnostics Ltd., Sanofi, Sunpharma, Takeda Pharmaceuticals

    Market Trends

    The increasing prevalence of Type 2 Diabetes Mellitus is driving a paradigm shift towards more personalized treatment approaches, emphasizing the need for innovative therapies and comprehensive management strategies.

    Centers for Disease Control and Prevention (CDC)

    Type 2 Diabetes Mellitus Treatment Market Market Drivers

    Rising Prevalence of Type 2 Diabetes

    The increasing prevalence of Type 2 Diabetes Mellitus globally is a primary driver for the Global Type 2 Diabetes Mellitus Treatment Market Industry. As lifestyle changes and dietary habits contribute to higher obesity rates, the World Health Organization indicates that the number of adults with diabetes has risen significantly. In 2024, the market is projected to reach 18.9 USD Billion, reflecting the urgent need for effective treatment options. This trend is expected to continue, with estimates suggesting that by 2035, the market could expand to 51.4 USD Billion, highlighting the growing demand for innovative therapies and management solutions.

    Market Segment Insights

    Regional Insights

    Key Companies in the Type 2 Diabetes Mellitus Treatment Market market include

    Industry Developments

    • Q2 2025: ADA 2025: Advances in Type 2 Diabetes Management With Tirzepatide At the 85th Scientific Sessions of the American Diabetes Association in June 2025, Eli Lilly's tirzepatide (Mounjaro, Zepbound) was highlighted for its unique mechanism and clinical data supporting its use in type 2 diabetes management. The session provided updated insights into tirzepatide’s FDA-approved indications and its role in personalized treatment plans.

    Type 2 Diabetes Mellitus Treatment Market Regional Analysis

    The Americas dominate the type 2 diabetes mellitus treatment market owing to the presence of patient population, a well-developed technology, high healthcare expenditure, and the presence of the leading players. Due to the rising prevalence of diabetes, various companies, and government associations are actively participating in improving diabetes care. For instance, The Merck Foundation has provided funding of around USD 10,000,000 for the projects designed to improve diabetes care in the United States.

    Europe holds the second position in the type 2 diabetes mellitus treatment market. It is expected that the government support towards research & development expenditure and amendments in reimbursement policies in the healthcare is likely to drive the European market. As per the German maternity guidelines, every pregnant woman can undergo glucose challenge test for the early diagnosis of Gestational diabetes mellitus, and the charges for the test are completely covered by women’s health insurance.

    Asia Pacific is the fastest growing type 2 diabetes mellitus treatment market owing to a huge patient pool, increasing demand, and development in healthcare technology.

    The Middle East & Africa holds the lowest share of the global market due to low development, lack of technical knowledge, and poor medical facilities.

    Type 2 Diabetes Mellitus Treatment Market Key Players

    Some of key the players in the global type 2 diabetes mellitus treatment market are: 

    • Abbott Laboratories
    • Acon Laboratories, Inc.
    • Adocia
    • Akros Pharma
    • Amgen
    • AstraZeneca
    • Bayer AG
    • Becton 
    • Dickinson and Company
    • Biocon
    • Boehringer Ingelheim
    • Daiichi Sankyo
    • Eli Lilly
    • Merck
    • Novartis & Co.
    • Novo Nordisk
    • Peptron
    • Pfizer
    • Roche Diagnostics Ltd.
    • Sanofi
    • Sunpharma
    • Takeda Pharmaceuticals

    Intended Audience

    • Pharmaceutical Companies
    • Medical Device Companies
    • Research and Development (R&D) Companies
    • Diagnostic Laboratories
    • Government Research Institute
    • Academic Institutes and Universities

    Future Outlook

    Type 2 Diabetes Mellitus Treatment Market Future Outlook

    The Type 2 Diabetes Mellitus Treatment Market is projected to grow at a 9.54% CAGR from 2024 to 2032, driven by increasing prevalence, technological advancements, and rising healthcare expenditure.

    New opportunities lie in:

    • Develop personalized medicine approaches to enhance treatment efficacy and patient adherence.
    • Invest in digital health solutions for remote monitoring and management of diabetes.
    • Expand access to affordable treatment options in emerging markets to capture new patient demographics.

    By 2035, the market is expected to exhibit robust growth, reflecting advancements in treatment and increased global awareness.

    Market Segmentation

    Type 2 Diabetes Mellitus Treatment Market Segmentation

    Intended Audience
    • Pharmaceutical Companies
    • Medical Device Companies
    • Research and Development (R&D) Companies
    • Diagnostic Laboratories
    • Government Research Institute
    • Academic Institutes and Universities

    Report Scope

    Report Attribute/Metric Details  
      Market Size   USD 39.18 Billion by 2032  
      CAGR   9.45%  
      Base Year 2023  
      Forecast Period   2024-2032  
      Historical Data Market Size 2023 18.53 (USD Billion)
      Forecast Units Market Size 2024 18.86 (USD Billion)
      Report Coverage Market Size 2032 39.18 (USD Billion)
      Segments Covered Compound Annual Growth Rate (CAGR) 9.45 % (2024 - 2032)
      Geographies Covered Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Key Vendors Base Year 2023
      Key Market Opportunities Market Forecast Period 2024 - 2032
      Key Market Drivers Historical Data 2018-2022

     

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    1. Table of Contents
    2. Chapter 1.    Report Prologue  
    3.  
    4. Chapter 2.    Market Introduction    
      1.     Definition    
      2.     Scope
    5. of the Study    
      1.     Research Objective  
        1.     Assumptions    
        2.   
    6.  Limitations    
    7. Chapter 3.    Research
    8. Methodology
      1.     Introduction
      2.     Primary
    9. Research    
      1.     Secondary research  
      2.     Market Size Estimation
    10. Chapter 4.  
    11.  Market Dynamics
      1.     Drivers    
      2.   
    12.  Restrains
      1.     Opportunities    
      2.   
    13.  Challenges
      1.     Macroeconomic Indicators
      2.   
    14.  Technology Trends & Assessment          
    15. Chapter 5.    Market Factor Analysis
      1.   
    16.  Porter’s Five Forces Analysis
      1.     Bargaining
    17. Power of Suppliers    
      1.     Bargaining Power
    18. of Buyers
      1.     Threat of New Entrants    
        1.     Threat of Substitutes    
        2.   
    19.  Intensity of Rivalry    
      1.     Value Chain
    20. Analysis
      1.     Investment Feasibility Analysis  
      2.     Pricing Analysis
    21. Chapter 6.    Global
    22. Type 2 diabetes mellitus treatment Market, by treatment
      1.     Introduction
      2.     Drug Class
        1.     Market Estimates
    23. & Forecast, 2020 – 2027
      1.     Devices
        1.   
    24.  Market Estimates & Forecast, 2020 – 2027
      1.     Others
        1.     Market Estimates & Forecast, 2020 – 2027
    25. Chapter 7.    Global Type 2 diabetes mellitus treatment Market,
    26. by End User
      1.     Introduction
      2.     Hospitals 
        1.     Market Estimates & Forecast, 2020 – 2027
      3.     Clinics
        1.     Market Estimates &
    27. Forecast, 2020 – 2027
      1.     Diagnostic Centers
        1.   
      2.     Drug
    28. Stores
      1.     Market Estimates & Forecast, 2020 –
    29. 2027
      1.     Pharmacies
        1.     Market Estimates
      2.     Others
        1.   
    30. Chapter 8.  
    31.  Global Type 2 diabetes mellitus treatment Market, by Region
      1.   
    32.  Introduction
      1.     Americas
        1.     North
    33. America
      1.     U.S.
        1.     Canada
        2.     South America
      2.     Europe
        1.   
    34.  Western Europe
      1.     Germany
        1.   
    35.  France
      1.     Italy
        1.     Spain
        2.     Eastern Europe
      2.     Asia Pacific
        1.     Japan
        2.     China
        3.   
    36.  India
      1.     Australia
        1.     Republic
    37. of Korea
      1.     Rest of Asia Pacific
      2.   
    38.  The Middle East & Africa
      1.     United Arab Emirates
        1.      Saudi Arabia
        2.     Oman
        3.   
    39.  Kuwait
      1.     Qatar
        1.     Rest
    40. of the Middle East & Africa
    41. Chapter 9    Company Landscape  
      1.     Introduction    
      2.   
    42.  Market Share Analysis    
      1.     Key Development
    43. & Strategies    
      1.     Key Developments  
    44. Chapter 10    Company Profiles    
      1.     Abbott Laboratories 
        1.     Company
    45. Overview    
      1.     Types Overview  
        1.     Financials    
        2.   
    46.  SWOT Analysis    
      1.     AstraZeneca  
        1.     Company Overview    
        2.   
    47.  Types Overview    
      1.     Financial
        1.     Key Developments  
        2.     SWOT Analysis    
      2.   
    48.  Eli Lilly
      1.     Company Overview    
        1.     Types Overview    
        2.   
    49.  Financial Overview
      1.     Key Development  
        1.     SWOT Analysis    
      2.   
    50.  Merck
      1.     Company Overview    
        1.     Types/Business Segment Overview    
        2.     Financial Overview    
        3.   
    51.  Key Development    
      1.     SWOT Analysis  
      2.     BECTON, DICKINSON AND COMPANY
        1.   
    52.  Company Overview    
      1.     Types Overview  
        1.     Financial overview    
        2.   
    53.  Key Developments    
      1.     Sanofi  
        1.     Company Overview    
        2.   
        3.     Financial
        4.     Key Developments  
      2.     BOEHRINGER INGELHEIM
        1.   
    54.  Overview    
      1.     Types Overview  
        1.     Financials    
        2.   
        3.     SWOT Analysis  
    55.         10.8    Others
    56. Chapter 11    MRFR Conclusion    
      1.   
    57.  Key Findings    
      1.     From CEO’s
    58. View Point    
      1.     Unmet Needs of the Market  
      2.     Key Companies to Watch    
      3.     Prediction of Type 2 diabetes mellitus treatment industry
    59. Chapter 12    Appendix
    60. LIST OF TABLES
    61. Table
    62. 1        Type 2 diabetes mellitus treatment Industry
    63. Synopsis, 2020 – 2027
    64. Table 2        Type
    65. diabetes mellitus treatment Market Estimates and Forecast, 2020 – 2027,
    66. (USD Million)
    67. Table 3        Type 2 diabetes
    68. mellitus treatment Market by Region, 2020 – 2027, (USD Million)
    69. 4        Type 2 diabetes mellitus treatment Market
    70. by Treatment, 2020 – 2027, (USD Million)
    71. Table 5      
    72.  Type 2 diabetes mellitus treatment Market by End Users, 2020 – 2027,
    73. Table 6     North America Type 2 diabetes mellitus
    74. treatment Market by Treatment, 2020 – 2027, (USD Million)
    75. Table 7   
    76.  North America Type 2 diabetes mellitus treatment Market by End Users, 2020
    77. – 2027, (USD Million)
    78. Table 8     US Type 2 diabetes mellitus
    79. Table 9   
    80.  US Type 2 diabetes mellitus treatment Market by End Users, 2020 – 2027,
    81. Table 10    Canada Type 2 diabetes mellitus treatment
    82. Market by Treatment, 2020 – 2027, (USD Million)
    83. Table 11  
    84.  Canada Type 2 diabetes mellitus treatment market by End Users, 2020 –
    85. 2027, (USD Million)
    86. Table 12    South America Type 2 diabetes
    87. mellitus treatment Market by Treatment, 2020 – 2027, (USD Million)
    88. 13    South America Type 2 diabetes mellitus treatment Market by
    89. End Users, 2020 – 2027, (USD Million)
    90. Table 14    Europe
    91. Type 2 diabetes mellitus treatment Market by Treatment, 2020 – 2027, (USD
    92. Million)
    93. Table 15    Europe Type 2 diabetes mellitus treatment
    94. Market by End Users, 2020 – 2027, (USD Million)
    95. Table 16  
    96.  Western Europe Type 2 diabetes mellitus treatment Market by Treatment, 2020
    97. Table 17    Western Europe Type
    98. diabetes mellitus treatment Market by End Users, 2020 – 2027, (USD Million)
    99. Table 18    Eastern Europe Type 2 diabetes mellitus treatment Market
    100. Table 19    Eastern
    101. Europe Type 2 diabetes mellitus treatment Market by End Users, 2020 – 2027,
    102. Table 20    Asia Pacific Type 2 diabetes mellitus
    103. Table 21  
    104.  Asia Pacific Type 2 diabetes mellitus treatment market by End Users, 2020
    105. Table 22    The Middle East &
    106. Africa Type 2 diabetes mellitus treatment Market by Treatment, 2020 – 2027,
    107. Table 23    The Middle East & Africa Type
    108. LIST OF FIGURES
    109. Figure 1    Research Process
    110. Figure 2    Segmentation for Type 2 diabetes mellitus treatment
    111. Market
    112. Figure 3    Segmentation Market Dynamics for Type 2 diabetes
    113. mellitus treatment Market
    114. Figure 4    Global Type 2 diabetes
    115. mellitus treatment market Share, by Treatment 2020
    116. Figure 5    Global
    117. Type 2 diabetes mellitus treatment market Share, by End Users, 2020
    118. Figure
    119. 6    Global Type 2 diabetes mellitus treatment market Share, by Region,
    120. 2020
    121. Figure 7    North America Type 2 diabetes mellitus treatment
    122. market Share, by Country, 2020
    123. Figure 8    Europe Type 2 diabetes
    124. mellitus treatment market Share, by Country, 2020
    125. Figure 9    Asia
    126. Pacific Type 2 diabetes mellitus treatment market Share, by Country, 2020
    127. 10    Middle East & Africa Type 2 diabetes mellitus treatment
    128. Figure 11    Global Type 2 diabetes
    129. mellitus treatment market: Company Share Analysis, 2020 (%)
    130. Figure 12  
    131.  Abbott Laboratories: Key Financials
    132. Figure 13    Abbott
    133. Laboratories: Segmental Revenue
    134. Figure 14    Abbott Laboratories:
    135. Geographical Revenue
    136. Figure 15    AstraZeneca: Key Financials
    137. Figure 16    AstraZeneca: Segmental Revenue
    138. Figure 17  
    139.  AstraZeneca: Geographical Revenue
    140. Figure 18    Eli Lilly:
    141. Key Financials
    142. Figure 19    Eli Lilly: Segmental Revenue
    143. Figure 20    Eli Lilly: Geographical Revenue
    144. Figure 21  
    145.  Merck: Key Financials
    146. Figure 22    Merck: Segmental Revenue
    147. Figure 23    Merck: Geographical Revenue
    148. Figure 24  
    149.  BECTON, DICKINSON AND COMPANY: Key Financials
    150. Figure 25    BECTON,
    151. DICKINSON AND COMPANY: Segmental Revenue
    152. Figure 26    BECTON,
    153. DICKINSON AND COMPANY Geographical Revenue
    154. Figure 27    Sanofi:
    155. Figure 28    Sanofi: Segmental Revenue
    156. 29    Sanofi: Geographical Revenue
    157. Figure 30    BOEHRINGER
    158. INGELHEIM: Key Financials
    159. Figure 31    BOEHRINGER INGELHEIM:
    160. Segmental Revenue
    161. Figure 32    BOEHRINGER INGELHEIM: Geographical
    162. Revenue

    Type 2 Diabetes Mellitus Treatment Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials